We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.045 | 2.07% | 2.22 | 2.10 | 2.22 | 2.22 | 2.22 | 2.22 | 228,080 | 09:03:56 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.90 | 7.23M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/1/2018 09:06 | Dontshout, Work backwards from those numbers; Taking the higher of the two, £100 a share with current share price (for ease at £2 and mkt cap £250mln) so £100 = £12.5bln Can/could such a valuation be justified or arrived at using p/e multiples with the sales potential alluded to by the BOD here? | sportbilly1976 | |
03/1/2018 09:03 | Will everyone please check their local village, I think one out there is missing an idiot. | hamhamham1 | |
03/1/2018 09:02 | I know it seems too good to be true but is it really so airy to imagine a company that has such a strong potential as Immupharma’s offering of halting or giving leads to - may I dare to wish,- starting cures, with its patented P140 etcetera etcetera, at least 7 major world-wide diseases, each of which affects many millions of people, to be worth at least seven times what it may sell Lupuzor for? Modern medicine is now making amazing breakthroughs every month. Why couldn't this one be one of the great breakthroughs? Its record thus far is heart-warming to say the least. I have decades of experience in winning and losing a lot, and it may sound ridiculous and I don't want to sound madly optimistic, but is £80 or £100 per share really too far out of the question? | dontshoutatonce | |
03/1/2018 08:54 | Sounds ghastly | longshanks | |
03/1/2018 08:53 | great thanks | qs99 | |
03/1/2018 08:48 | hamhamham Do you think you are safe to make comments like that just because I said I was going when njb67 was gone? Well you are not. Good - I am delighted I have upset you again. It is a pity that he has left you, his ponderous, sycophant wingman and angry young lady zho behind. If you bothered to properly read posts you would know my price prediction is far far less then £100 | runtoma | |
03/1/2018 08:37 | Last evaluation is 28 days after last dose, which was announced on 21/12/2017, so last dose might have been the day before to which you then add 28 days. | hottingup | |
03/1/2018 08:31 | They released the RNS on the 21st, if you add 28 days ( which was their dosing regimen which they said its fixed ) we should expect an RNS on the 18th, which is a thursday | immy1992 | |
03/1/2018 08:20 | Someone mentioned the 17th Jan didn't they? DYOR etc....would be useful to know the exact day, anyone know? thanks | qs99 | |
03/1/2018 08:08 | The Phase 3 can be unblinded in around two weeks from now and we could see it break through the £40 level if the results beat Benlysta. | englishlongbow | |
03/1/2018 07:44 | IMM have two platforms. Gilhead just paid over $11 billion to get Kite's platform. | money maker1 | |
03/1/2018 07:24 | If Imm have a drug that can generate multi billion pound sales the value of the company is a multiple of those sales, and even more if they have an entire platform applicable to multiple diseases. | stealth wealth | |
03/1/2018 07:04 | Runt. When will you learn that just because anyone (eg njb67) doesn't think the share is going to hit £100, that isn't negativity, in fact some may say it's objectivity. You are by far the most annoying poster on here. | hamhamham1 | |
03/1/2018 02:21 | Just having breakfast by the pool, 27c clear, nice breeze, hope it’s not too cold in blighty. By the time trading starts in paradise i’m Expecting a record number of green thumbs up 😁 | ny boy | |
03/1/2018 01:54 | The Finn cap 237p valuation is based on pre fda approval etc as far as I am aware. Just a guide, no one knows how high we can go here, it’s partly the fear of losing out and less stock available as investors buy to generally hold. Any future tree shakes can provide useful top up opportunities. GLA | ny boy | |
02/1/2018 23:16 | The more logical comparisons are with other pharma companies like HGSi and Kite Pharma, whose market caputalisations went ballstic. | top tips | |
02/1/2018 23:04 | GKP... grrrrr | reptile3 | |
02/1/2018 22:54 | Some of the valuations quoted here remind me of the glory days of GKP. It was going to make thousands of millionaires overnight, just look at what happened and how many disappointed investors were left to lick their wounds. I don't have a figure for what IMM will be worth if it gets full approvals, all I know it will be a bigger number than now, that's why I am a long term holder | ayl30 | |
02/1/2018 21:59 | He will be back under a new alias, probably already operating in a different one anyway. This much is guaranteed judging by his reactive posts. We are not naieve here are we folks? | andyr42 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions